Eli Lilly's Trading Volume Plummets 38.45% to 24th Position
1min read On April 10, 2025, Eli Lilly and Company (LLY) experienced a significant decline in trading volume, with a total of 29.40 billion shares traded, marking a 38.45% decrease from the previous day. This drop placed LLY at the 24th position in terms of trading volume for the day. The stock price of LLY also decreased by 4.35%.
Eli Lilly and Company recently disclosed $60,000 in lobbying expenses for the first quarter of 2025. The lobbying efforts focused on healthcare and trade-related issues, reflecting the company's ongoing engagement with regulatory bodies and policymakers.
In the past six months, members of Congress have actively traded LLY stock, with a total of 18 transactions recorded. Notably, Representative Josh Gottheimer made 12 sales, totaling up to $180,000, while Senator Ron Wyden conducted one purchase and one sale, each worth up to $100,000. Representative Marjorie Taylor Greene made two purchases worth up to $30,000, and Representative Greg Landsman sold up to $50,000. Senator Sheldon Whitehouse purchased up to $50,000 in LLY stock.
Insider trading activity for LLY has been predominantly on the sell side, with 56 sales and no purchases recorded in the past six months. Endowment Inc. Lilly sold 534,452 shares for an estimated $474,544,560, while Daniel Skovronsky, Executive Vice President and Chief Scientific Officer, sold 5,000 shares for approximately $4,316,064. Donald A. Zakrowski, Senior Vice President of Finance and Chief Accounting Officer, sold 1,900 shares for around $1,541,282.
Institutional investors have shown mixed sentiment towards LLY, with 1,663 adding shares to their portfolios and 1,617 reducing their positions in the most recent quarter. Gamma Investing LLC significantly increased its holdings by 103,831.6%, adding 14,852,076 shares worth an estimated $12,266,478,089. Proficio Capital Partners LLC also added 5,197,038 shares, increasing its portfolio by 100,387.1%. Conversely, JPMorgan Chase & Co. reduced its holdings by 17.9%, removing 3,259,646 shares, and FMR LLC decreased its position by 7.6%, selling 2,501,172 shares.
Analysts have generally maintained a positive outlook on LLY, with three firms issuing "Outperform" ratings in the past several months. Leerink Partners, BMO Capital, and Bernstein have all recommended the stock, reflecting confidence in the company's future performance. Multiple analysts have set price targets for LLY, with a median target of $990.0. Morgan Stanley's analyst set a target price of $1,146.0, while Leerink Partners' Andrew Berens and Berenberg Bank's Kerry Holford set targets of $950.0 and $970.0, respectively. BMO Capital's Evan David Seigerman also set a target of $1,010.0, indicating a bullish sentiment among analysts.
